Hutchmed commences Phase I trial of solid tumours therapy in China
Hutchmed has started a Phase I clinical trial to evaluate its investigational therapy, HMPL-653, for the treatment of patients with advanced malignant solid tumours and…
Filing Analytics
Pharma Sector Filing Sentiment Score (Last 12 months)
Pharma Sector Trending Regions in Company Filings (Last 12 months)
Top 10 Pharma Companies Filing Themes - 2020 Vs. 2019 and Top Companies in 2020
| Top 10 Themes | 2020 Rank | 2019 Rank | Top 5 Companies with Themes Mentions in 2020 |
|---|---|---|---|
| Demographics | 1 | 1 | Moderna Inc | Axcella Health Inc | Alnylam Pharmaceuticals Inc | Denali Therapeutics Inc | Allogene Therapeutics Inc |
| Geopolitics | 2 | 2 | BeiGene (Beijing) Co Ltd | AstraZeneca Plc | FibroGen Inc | F. Hoffmann-La Roche Ltd | Hutchmed China Ltd |
| M&A | 3 | 3 | Alexion Pharmaceuticals Inc | Emergent BioSolutions Inc | Akebia Therapeutics Inc | Pfizer Inc | Charles River Laboratories International Inc |
| Cybersecurity | 4 | 4 | Alnylam Pharmaceuticals Inc | Akebia Therapeutics Inc | Vir Biotechnology Inc | BioMarin Pharmaceutical Inc | Denali Therapeutics Inc |
| China Impact | 5 | 5 | BeiGene (Beijing) Co Ltd | Hutchmed China Ltd | FibroGen Inc | Athenex Inc | Zai Lab Ltd |
| Emerging Economies | 6 | 6 | Apollo Hospitals Enterprise Ltd | Cipla Ltd | Glenmark Pharmaceuticals Ltd | Sun Pharmaceutical Industries Ltd | AstraZeneca Plc |
| Climate Change | 7 | 7 | Novartis AG | Orion Corp | Shionogi & Co Ltd | Merck KGaA | Bayer AG |
| Workplace Safety | 8 | 8 | Novartis AG | Orion Corp | Merck KGaA | Lumos Pharma Inc | Recordati SpA |
| Big Data | 9 | 9 | Moderna Inc | F. Hoffmann-La Roche Ltd | Axcella Health Inc | Inovio Pharmaceuticals Inc | BioXcel Therapeutics Inc |
| Artificial Intelligence | 10 | 10 | F. Hoffmann-La Roche Ltd | Moderna Inc | Oncotelic Therapeutics Inc | Apollo Hospitals Enterprise Ltd | Sanofi |
Pharma Sector Filing Mentions (Last 12 months)
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Latest News
View More
Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Lynk Pharmaceuticals has dosed the first patient with its drug LNK01001 in a Phase II clinical trial for the treatment of ankylosing spondylitis, a chronic…
Sorrento secures Brazil clearance to start Phase IIa long Covid trial
Sorrento Therapeutics has secured the Brazilian health regulatory agency ANVISA authorisation to commence a Phase IIa clinical trial of COVI-MSC…
Eisai enrols first patient in Phase II/III Alzheimer’s disease antibody trial
Eisai has enrolled the first subject in the Phase II/III Tau NexGen clinical trial of its investigational anti-microtubule binding region…
Resverlogix starts Phase IIb oral Covid-19 drug trial
Resverlogix has initiated subject enrolment and dosing in a Phase IIb clinical trial of its small molecule therapeutic candidate, apabetalone (RVX-208),…
IACT Health, LMC Manna, True North merge to form Centricity Research
Clinical research companies IACT Health, LMC Manna Research, and True North Clinical Research have joined forces and announced the formation…
Company A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
